Primary repair versus surgical and transcatheter palliation in infants with tetralogy of Fallot by Dorobantu, Dan M et al.
                          Dorobantu, D. M., Mahani, A. S., Sharabiani, M. T. A., Pandey, R., Angelini,
G. D., Parry, A. J., ... Stoica, S. C. (2018). Primary repair versus surgical and





Link to published version (if available):
10.1136/heartjnl-2018-312958
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via BMJ at https://heart.bmj.com/content/104/22/1864. Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published




Primary repair versus surgical and transcatheter palliation in infants with tetralogy of Fallot 
 
Dan M. Dorobantu1, 2, Alireza S. Mahani3, Mansour TA. Sharabiani4, Ragini Pandey1, Gianni Angelini5, 
Andrew J. Parry1, Robert Tulloh1, 5, Robin P. Martin1, Serban C. Stoica1, 5 
1. Cardiac Surgery Department, Bristol Royal Hospital for Children, University Hospital Bristol NHS 
Trust, Bristol, United Kingdom 
2. Cardiology Department, “Prof. CC Iliescu” Emergency Institute for Cardiovascular Diseases, 
Bucharest, Romania 
3. Davidson Kempner Capital Management, New York City, NY, United States of America 
4. Statistics Department, Royal Marsden Hospital, Royal Brompton NHS Trust, London, United 
Kingdom 
5. School of Clinical Sciences, University of Bristol, Bristol, United Kingdom 
Corresponding author 
Dan M. Dorobantu 
Department of Cardiology, “Prof. C.C. Iliescu” Emergency Institute for Cardiovascular 
Diseases, 022322 Sos Fundeni 258, Bucharest, Romania. 
dn.dorobantu@gmail.com 
Abstract word count: 246 
Manuscript word count: 2970 
 
All authors declare no disclosures relevant to this paper.   
2 
 
Objectives: Treatment of infants with tetralogy of Fallot (ToF) has evolved in the last 2 decades with 
increasing use of primary surgical repair (PrR) and transcatheter right ventricular outflow tract palliation 
(RVOTd), and fewer systemic-to-pulmonary shunts (SPS). We aim to report contemporary results using 
these treatment options in a comparative study. 
Methods: This a retrospective study using data from the UK National Congenital Heart Disease Audit. All 
infants (n=1662, median age 181 days) with ToF and no other complex defects undergoing repair or 
palliation between 2000 and 2013 were considered. Matching algorithms were used to minimize 
confounding due to lower age and weight in those palliated.  
Results: Patients underwent PrR (n=1244), SPS (n=311) or RVOTd (n=107). Mortality at 12 years was 
higher when repair or palliation was performed before the age of 60 days rather than after, most significantly 
for primary repair (18.7% vs 2.2%, p<0.001), less so for RVOTd (10.8% vs 0%, p=0.06) or SPS (12.4% vs 
8.3%, p=0.2). In the matched groups of patients, RVOTd was associated with more right ventricular outflow 
tract (RVOT) reinterventions (HR=2.3, p=0.05 vs PrR, HR=7.2, p=0.001 versus SPS) and fewer pulmonary 
valve replacements (PVR) (HR=0.3 vs PrR, p=0.05) at 12 years, with lower mortality after complete repair 
(HR=0.2 versus PrR, p=0.09).  
Conclusions: We found that RVOTd was associated with more RVOT reinterventions, fewer PVR and 
fewer deaths when compared with PrR in comparable, young infants, especially so in those under 60 days 
at the time of the first procedure.  
Key words: tetralogy of Fallot, primary repair, RVOT stenting, Blalock-Taussig shunt  
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What is already known about this subject? 
Early primary repair, palliation by use of a systemic to pulmonary shunt and right outflow tract dilation and 
stenting are all considered to be acceptable alternatives for treating symptomatic infants with tetralogy of 
Fallot. It is not known how they compare to one another.     
What does this study add? 
Very few studies compare primary repair and palliation alternatives in tetralogy of Fallot. The current study 
shows that all three methods of treatment had good results, but palliation by right ventricular outflow tract 
dilation was associated with fewer pulmonary valve replacements and fewer deaths. Additionally, in infants 
undergoing primary repair, age under 60 days and the need for transannular patching and pulmonary artery 
interventions were associated with poorer outcomes. 
How might this impact on clinical practice? 
In treating symptomatic infants under 60 days of age, palliation by right ventricular outflow tract dilation 
might be preferable to primary repair. Systemic to pulmonary shunts still offer an alternative in patients 
with low surgical risk. If primary repair is performed, transannular patching and pulmonary artery 




There are several options available for treating symptomatic infants with tetralogy of Fallot (ToF), including 
primary surgical repair (PrR), palliation with a systemic-to-pulmonary (SPS) shunt and the more recent 
palliation by right ventricular outflow tract or pulmonary valve dilation (RVOTd), with ductal stenting 
being less frequent. 
Before the improvement in surgical techniques, perioperative care and the advent of transcatheter palliation 
procedures, the preferred treatment for symptomatic infants was an early SPS and then an elective 
secondary complete repair (ScR) subsequently. Data emerging on high mortality and complication rates 
following neonatal SPS[1] have led to alternative options to be explored, with early PrR (before 3 months) 
and transcatheter palliation gaining traction.[2]  
Currently there is no consensus regarding the best strategy, with reports of good results with both early or 
neonatal repair[3,4], RVOTd[5] and even SPS[2]. We have previously shown that among all lesions with 
pulmonary obstruction, ToF had the lowest mortality after SPS palliation, with fewer such procedures being 
performed in these patients each year, likely due to better patient selection.[6] At the same time, all options 
have disadvantages: early PrR can increase the need for a transannular patch and late morbidity, SPS has 
high rates of complications while RVOTd is associated with valve lesions and reinterventions.[2] 
There are only a few studies directly comparing these management strategies, but with  inherent differences 
amongst the compared groups, since each center will have different practices.[3,5] There is a need for a 
direct comparative study with sufficient data to allow for adjusting for these differences. A national registry 
can offer both the large population and the good quality data required for such a study.  
The National Congenital Heart Disease Audit (NCHDA) collects data on all cardiac procedures performed 
for congenital heart disease in the United Kingdom. In this study we aim to: 1) describe contemporary 
practice and trends; 2) compare PrR, SPS palliation and RVOTd outcomes in matched groups; and, 3) 




Patient selection and classification 
National data collection has been previously described.[7] All but 4 (0.2%) of patients in the final dataset 
have survival data. Data on 5616 patients with ToF treated between 2000-2013 were available. We excluded 
the following patients: 2084 born before the registry was created, therefore without complete procedural 
history, 871 aged over 1 year at first procedure, 489 from overseas, Scotland or Ireland, 332 with other 
complex cardiac defects (transposition of great arteries, corrected transposition of great arteries, double 
outlet right ventricle, complete atrioventricular septal defect, double chambered right ventricle, cor 
triatriatum, total anomalous pulmonary connection, single ventricle morphology, ventricle imbalance, 
isomerism, pulmonary valve atresia, tricuspid atresia, mitral atresia), 37 with major aorto-pulmonary 
collateral arteries, 118 with miscellaneous data errors (empty data fields, diagnosis/procedure code errors), 
and 23 with other initial procedures than those of interest. This resulted in 1662 patients undergoing 2364 
procedures including reinterventions - pulmonary valve replacements (PVR), SPS, pulmonary artery (PA) 
or right ventricular outflow tract (RVOT) reinterventions. 
Statistical Analyses 
Frequencies are given as absolute numbers and percentages, continuous values as median (inter-quartile 
range). Short term outcomes are calculated based on 30 day data. Population characteristics were compared 
using the Mann-Whitney, Student-t and the Fisher exact tests.  
Estimates of long term outcomes are made with the Kaplan-Meier method using mortality (all cause) and 
reintervention (any, SPS, RVOT non PVR, PA and PVR), calculated before repair (for SPS and RVOTd), 
after repair and for the full follow-up (for all 3 groups, from first procedure to end). Rates of next event 
(Supplemental Table IV) are estimated using the data obtained after applying the modulated renewal 
approach.[6] When considering reintervention outcomes by type, surgical and transcatheter procedures of 
the same nature were considered as one event type (RVOT and PA reinterventions respectively); PVR with 
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and without PA repair was also grouped as one reintervention type (PVR). This was done to maintain 
simplicity, on the premise that reinterventions in the same group were performed under similar indications.  
We conducted 3 additional analyses: pairwise three-way comparisons of procedures, and predictive models 
for each of the three procedure types. Matching was done using a stochastic augmentation with restriction 
methods (SAMUR package for R).[8,9] For both survival analysis after matching and the three predictive 
models, a Bayesian survival analysis using generalized Weibull approach was used (BSGW package for 
R).[10] To look at the effect of reinterventions in the predictive models, a modulated renewal approach was 
used.[6] Detailed statistical methods can be found in the Supplemental Material.  
Statistical analyses were done with STATA/IC 11.2 (StataCorp LP, College Station, TX) and R version 3.1 
(R Core Team, 2015).  
RESULTS 
A total of 1662 infants with ToF were included, with a median age of 181 (101-257) days, undergoing 
primary surgical repair (n=1244), SPS (n=311) or RVOTd (n=107) between 2000 and 2013, from 12 centers 
(mean patients/center 156, range 6-281). There was a trend for fewer SPS procedures and more PrRs and 
RVOTd observed during this period (Figure 1).  
Demographic, clinical and procedural data, regarding the initial procedure can be seen in Table 1; data on 
ScR and reinterventions are shown in the Supplemental Table I. Of note are the significant differences in 
population characteristics, especially age and weight. A schematic of the treatment pathways is presented 
in Figure 2.  
By plotting survival curves in 30 day increments we found that mortality at 12 years is higher when repair 
or palliation is performed before the age of 60 days rather than after, most significantly for PrR (18.7% vs 
2.2% after, p<0.001), less so for RVOTd (10.8% vs 0%, p=0.06) or SPS (12.4% vs 8.3%, p=0.2). 
Unadjusted long-term outcomes are detailed in Supplemental Tables II and III. Short-term outcomes are 
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shown in Supplemental Table IV. Having a reintervention increased the risk of further reinterventions, in 
the whole population (p<0.001) but also for PrR (p<0.001), SPS (p=0.03) and RVOTd (p<0.001). 
Due to the significant differences in patient characteristics among the three groups of interest, we proceeded 
to perform matched-groups analyses. 
SPS versus RVOTd  
Patients with SPS and RVOTd were matched in a pairwise comparison. Differences in groups before and 
after matching are detailed in Supplemental Table V. 
RVOTd was associated with more RVOT (non-PVR) pre-repair reinterventions when compared to the SPS 
(p=0.001, Figure 3A). Post-repair outcomes did not differ significantly. This results in more overall 
reinterventions from initial palliation to follow-up after repair in the RVOTd group (p=0.01). Before and 
after matching comparison data are detailed in Table 3 and Supplemental Table VI. There were more 
complete repairs with transannular patches in the RVOTd group, with a similar proportion before and after 
matching (68% vs 53%, p=0.01 before, 68% vs 54%, p=0.07 after). 
PrR versus SPS versus RVOTd 
Patients in the PrR, SPS and RVOTd groups were matched in a three-way comparison. Differences in 
groups before and after matching are detailed in Supplemental Table VII. 
RVOTd was associated with more RVOT (non PVR) reinterventions (p=0.04, Figure 3B) from initial 
procedure onward. We found fewer PVRs overall in the SPS and RVOTd groups compared to PrR (p=0.05 
and 0.06 respectively, Figure 3C), with slightly fewer deaths after repair in the RVOTd group (p=0.09 
versus PrR, Figure 3D); all three associations were borderline statistically significant and not observed in 
the unmatched groups. Before and after matching comparison data are detailed in Table 4 and Supplemental 
Table VIII.  
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There were fewer complete repairs using a transannular patch in the PrR group, when compared to SPS and 
RVOTd respectively, both before matching (42% vs 47 vs 47%, p<0.001) and after matching (43% vs 55% 
vs 68%, p=0.003). 
Predictors of outcomes  
In addition to the comparison of possible treatment options, a multivariable analysis was performed for 
each main group separately, taking into consideration the subsequent procedures. We found that outcomes 
after PrR and palliation in infants with ToF are influenced by a vast array of factors, both patient related 
and procedure related. Supplemental Table IX shows all identified predictors. 
DISCUSSION 
Both primary repair and palliation in ToF are associated with higher mortality when performed before the 
age of 60 days, but the differences appear to be more significant when the choice is primary repair (more 
than 8 times higher). After matching was performed in all three options, thus selecting the youngest, highest 
risk infants, those undergoing initial RVOTd have more RVOT (non-PVR) reinterventions when compared 
to PrR, fewer PVRs and also fewer long term deaths, the latter not reaching statistical significance. These 
findings, although retrospective, suggest that in those infants under the age of 60 days palliation might offer 
better outcomes when compared to primary repair. Even so, there were numerous factors influencing the 
outcomes in each group, from patient age and size, to associated conditions, need for reinterventions and 
even procedure era.  
In the UK, as in most countries, the management of ToF varies between institutions.[11] The same patient 
might undergo palliation by SPS in one unit, RVOTd in another or PrR in the next, with no consensus on 
patient selection. No option is without its critics – early PrR might be associated with increased late 
morbidity due to use of transannular patching, SPSs have garnered a bad reputation due to complications, 
while RVOTd has yet to be adopted in all centers.[2,12] This is, to our knowledge, the first study to directly 
compare all three commonly used treatment options, while also adjusting for some confounding differences. 
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Previous studies comparing PrR to one palliation method or another[3,5] acknowledged procedural 
selection bias. By including all patients in a large geographical area we could compare patients which would 
potentially be candidates for all three options. 
Comparing palliation options 
Current palliation options are SPS, RVOTd and ductal stenting, the latter being rarely used for ToF in the 
UK.  RVOT dilation or stenting is usually chosen in babies with risk factors for surgery who tend to be 
smaller and sicke,[5,13] which is also true in our study. We found significantly more RVOT (non-PVR) 
reinterventions in the RVOTd group, the differences being observed only in the pre-repair period. We 
assume that even after matching, those in the RVOTd group would still represent a population with surgical 
risk factors, and as such the true benefits of the transcathateter approach might be underestimated.  As such 
RVOTd could be a comparable, if not superior, alternative to SPS palliation in similar patients. 
Comparing all three options  
There are situations when the decision to do a complete repair or a palliation in an infant depends on the 
centre practice. This is also true for neonates, even if there is considerable debate on whether the low early 
mortality is at the expense of long term morbidity.[2] There are few data on how these treatment options 
fare head-to-head, with no reports comparing all three simultaneously.  
At a glance, looking at the whole population of unmatched infants with ToF, PrR appears to have 
significantly better outcomes when compared to both palliation options. Such a comparison is misleading, 
as many times patients differ greatly – in our cohort those referred for palliation were younger, smaller, had 
poorer growth for age and more genetic conditions. The differences observed in an uninformed comparison 
can be due to treatment selection and not the procedures themselves. Having data from consecutive patients 
in 12 centres allowed us to limit the three-way comparison to groups with similar characteristics in terms 
of age, weight, somatic development and associated abnormalities; we aimed to include only patients who 
could have been selected in theory for any of the three options.  
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In this matched analysis all three treatments achieved somewhat comparable results, but with a few notable 
differences. There were more RVOT (non-PVR) reinterventions in the RVOTd group as found in previous 
studies[3,5], but without an increase in mortality and PVR.  Interestingly, we observed an overall lower 
risk of PVR in both palliation groups when compared to PrR, not just in one or the other, even if there were 
more secondary repairs using a transannular patch. In our study more than two thirds of the RVOTd 
procedures did not employ a stent, which would explain the much lower proportion of transannular patching 
(47% before matching, 68% after matching compared to 82% reported by Wilder et al and 100% by 
Sandoval et al, the latter using only stenting).[5,11] Quandt et al.  describe a large single centre experience 
with RVOT stenting in a variety of lesions, transannular patch usage being comparable to SPS.[13] In our 
study we observed that using a balloon rather than a stent increases the risk of SPS placement afterwards 
due to inadequate pulmonary blood flow. Whether a palliation strategy using repeat balloon dilation rather 
than stenting, in an effort to preserve the valve, is preferable is still to be determined.  
Previous reports described a high incidence of PA reinterventions after RVOTd.[5] After matching we 
found similar PA reintervention rates in all three groups.  More PA reinterventions were observed in the 
SPS and RVOTd groups only in overall, unmatched comparisons. This suggests that the differences 
previously described are more likely due to infants with less developed PA branches being referred more 
frequently to palliation rather than PrR. During follow-up the somatic growth of the PA branches “catches 
up” in these groups, which further support this conclusion.[5]  
Predictors of outcomes after PrR 
To our knowledge this is the largest group of unselected consecutive infants with ToF undergoing PrR 
reported to date. This allowed for a complex analysis, including the influence of reinterventions on 
subsequent events. 
The most discussed aspect of primary repair is age. There is no definitive age of “optimal” repair, and one 
might not be identified due to the large number of confounding factors. In our data when looking at age 
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increments of 30 days, we found a steep drop in late mortality when primary repair was performed after 
age 60 days (from 18.7% before 60 days to 2.2% after). 
In our study worse outcomes were associated with characteristics found in those patients with 
underdeveloped RVOTs and PAs, like smaller age, smaller weight for age (z-score), use of transannular 
patching, need for PA procedures at index or afterwards and genetic syndromes. Using a palliation method 
to allow for more somatic growth appears to be a preferable option, as both palliation methods appear to be 
comparable to PrR in these patients. Our finding, that using a transannular patch is associated with both 
increased mortality and future need for PVR, supports other data suggesting that a key aspect of repair is 
preserving the pulmonary valve when possible.[5] It is reassuring that reinterventions in the first 10 years 
after ToF repair are not associated with increased mortality, only with further subsequent reinterventions. 
Also, procedures performed in recent years have had a steadily decreasing mortality and PVR rate.   
Surgical PA repair at index is associated with increased mortality and a higher risk for further PA 
reinterventions. Additionally, PA reinterventions themselves, surgical or transcatheter, increase the chance 
for future such reinterventions. Wilder et al. concluded that aggressive patch augmentation for hypoplastic 
branch PAs might increase the reintervention rates, and suggest that after repair or palliation PA branches 
should develop well enough without further instrumentation.[14] Finding these associations between PA 
interventions and poorer outcomes in our multivariable models supports the notion that somatic growth 
rather than surgical patching should be preferred, when possible. PA arterioplasty performed at the time of 
PrR is associated with increased mortality, but not when done as a reintervention later on. This suggests 
that that allowing the PAs to grow before intervening might be the better option. 
Predictors of outcomes after SPS 
We found that smaller age and weight for age at SPS placement are associated with increased mortality, a 
well-documented fact.[1,6] PA repair, both at index and as a reintervention, is associated with more PA 
procedures, as was the case for PrR, further supporting the conclusion that patching the pulmonary arteries 
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instead of allowing for somatic growth might lead to poorer outcomes. This conclusion warrants further 
research.  
Predictors of outcomes after RVOT transcatheter palliation 
In multivariable analysis we did not identify any predictors of increased early mortality, but under the 
limitation of just 7 deaths. Taking into consideration that all deaths occurred in patients under 60 days, we 
can speculate that this age category remains a challenge, regardless of treatment. It is reassuring that 
RVOTd patients did not have a higher mortality compared to SPS and PrR, supporting the notion that 
RVOTd is an option in challenging cases when other methods are not feasible. [5,13] Patients with small 
age, genetic syndromes or where only a balloon dilation was used were at an increased risk for requiring 
further palliation by SPS placement. It is possible that the clinical scenario resulted in insufficient 
pulmonary flow, and an alternative palliation was used. The presence of a right aortic arch was strongly 
associated with SPS placements after RVOTd; this might be a spurious result, possibly confounded by 
surgical anatomy. In more recent years fewer SPS placements after RVOTd were observed, in the general 
context of SPS usage dropping in the UK.[6] 
Limitations 
The study is limited by absence of clinical data such as severity of symptoms, imaging, and the relatively 
short follow-up. It also has limitations inherent to a retrospective design, including the matching methods. 
In the three-way comparison, to balance the resulting groups’ size and the matching quality, some subgroup 
differences remain. Finally, neonatal primary repair is uncommon in the UK so our study offers little 
information regarding this option. 
Conclusions 
The UK database offered a unique insight into how the treatment options for infants with ToF compare. We 
found that RVOTd was associated with more RVOT reinterventions, fewer PVR and potentially fewer 
deaths when compared with PrR in young infants, especially so in those under 60 days at the time of the 
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first procedure. The role of primary repair and SPS in this high-risk group needs to be reevaluated, as is the 
use of transannular patching. 
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Table 1. Demographic, clinical and procedural data by initial procedure group 
 
All patients PrR SPS palliation 
RVOTd 
palliation p value 
 
n=1662 n=1244 (74.9) n=311 (18.7) n=107 (6.4) 
 
Patient data 
     










     Median weight; kg 
(IQR) 6.5 (5;7.7) 7 (6;8) 3.8 (3;5.1) 3.4 (2.7;4.4) <0.001 
     Median weight for 
age z score -1.2 (-2.2;-0.3) -1 (-1.9;-0.2) -1.9 (-3.3;-0.8) -2 (-3.4;-0.6) <0.001 
     Neonate (n,%) 162 (9.8) 14 (1.1) 101 (32.5) 47 (43.9) <0.001 
     Infant (n,%) 1500 (90.2) 1230 (98.9) 210 (67.5) 60 (56.1) 
 
     Female (n,%) 703 (42.3) 530 (42.6) 131 (42.1) 42 (39.2) 0.8 
     Median follow-up, 
years (IQR) 4.7 (2.1;8.6) 4.4 (2.1;8.2) 7 (2.8;10) 2.4 (1.4;6.5) <0.001 
     Associated defects 
(n,%)      
     ASD  76 (4.6) 60 (4.8) 11 (3.5) 5 (4.7) 0.59 
     Right aortic arch 88 (5.3) 49 (3.9) 34 (10.9) 5 (4.7) <0.001 
     Persistent SVC/IVC 59 (3.6) 39 (3.1) 16 (5.1) 4 (3.7) 0.25 
     PA 
stenosis/hypoplasia 61 (3.7) 40 (3.2) 14 (4.5) 7 (6.5) 0.12 
     PA non-confluence 5 (0.3) 2 (0.2) 3 (1) 0 0.12 
     Genetic syndromes 113 (6.8) 72 (5.8) 30 (9.7) 11 (10.3) 0.01 
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ASD = atrial septal defect; IQR = inter quartile range; IVC = inferior vena cava; PA = pulmonary artery; 
PVR = pulmonary valve replacement; RVOT = right ventricular outflow tract; RVOTd = right ventricular 





Table 2. Comparison between RVOTd and SPS in terms of mortality and reintervention in 
matched and unmatched groups 
 
Unmatched Matched 
Outcome Coefficient P value Coefficient P value 





    RVOT non PVR 1.98 <0.001 1.98 0.001 
    SPS reintervention or placement 1.08 0.002 0.76 0.09 
    PA 1.09 0.04 0.8 0.3 







    RVOT non PVR 1.16 <0.001 0.98 0.01 
    Any 0.74 <0.001 0.58 0.02 
Coefficients are for unadjusted RVOTd versus SPS comparison (positive coefficient 
represents an advantage for SPS). 
PA = pulmonary artery; PVR = pulmonary valve replacement; RVOT = right ventricular 
outflow tract; RVOTd = right ventricular outflow tract palliation; SPS = systemic-to-






Table 3. Comparison between PrR, SPS and RVOTd in terms of mortality and reintervention in 






ratio P value Hazard Ratio P value 
Post-repair death PrR Baseline  baseline 
 
 
SPS 1.16 0.7 0.32 0.3 
 
RVOTd 0.64 0.6 0.17 0.09 
Overall reintervention 
    





SPS 1.33 0.2 0.79 0.6 
 
RVOTd 4.52 <0.001 2.29 0.05 





SPS 1.56 0.1 0.41 0.05 
 
RVOTd 1.43 0.5 0.32 0.06 





SPS 2.16 <0.001 1.09 0.7 
 
RVOTd 4.8 <0.001 2.09 0.01 
PA = pulmonary artery; PVR = pulmonary valve replacement; RVOT = right ventricular outflow tract; 





Figure 1. Trends in treatment of ToF in infants in the UK. There is a decrease in the number of systemic 
to pulmonary shunts (SPS) in favor of an increase in both PrR and right ventricular outflow tract dilations 
(RVOTd) between 2000 and 2012. 
Figure 2. Cross-sectional summary of procedures performed in all infants with ToF treatment in the study. 
Initial palliation, subsequent reinterventions prior to complete repair, PrR and reinterventions in the post-
complete repair period are shown, chronologically from left to right.  
Figure 3.  Comparison between treatment options for ToF. All panels show survival curves fitted in a 
univariable Weibull regression after pairwise and three-way matching, respectively. A) Freedom from 
RVOT (non-PVR) reintervention in SPS and RVOTd groups before complete repair - comparison after 
matching B) Overall freedom from RVOT (non-PVR) reintervention in PrR, SPS and RVOTd groups – 
comparison after matching C) Overall freedom from PVR in PrR, SPS and RVOTd groups D) Survival 
after complete repair in PrR, SPS and RVOTd groups.  
